Medpace Holdings Inc
$ 567.56
-0.75%
26 Dec - close price
- Market Cap 15,987,157,000 USD
- Current Price $ 567.56
- High / Low $ 571.85 / 561.83
- Stock P/E 39.69
- Book Value 10.27
- EPS 14.30
- Next Earning Report 2026-02-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.74 %
- 52 Week High 626.25
- 52 Week Low 250.05
About
Medpace Holdings, Inc. is a leading global provider of integrated clinical research services, specializing in the pharmaceutical, biotechnology, and medical device sectors. Based in Cincinnati, Ohio, the company harnesses its deep industry expertise across North America, Europe, and Asia to deliver comprehensive support throughout the clinical development process, from initial feasibility to regulatory submission. Known for its steadfast commitment to quality and regulatory compliance, Medpace facilitates the timely transition of clients' products from development to market approval. With a robust operational infrastructure and a talented workforce, Medpace is well-positioned to drive innovation and growth in the evolving clinical research landscape.
Analyst Target Price
$541.92
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 | 2023-07-24 | 2023-04-24 | 2023-02-13 |
| Reported EPS | 3.86 | 3.103 | 3.67 | 3.6813 | 3.01 | 2.75 | 3.2 | 2.46 | 2.22 | 1.93 | 2.27 | 2.12 |
| Estimated EPS | 3.53 | 2.99 | 3.0775 | 3.1167 | 2.78 | 2.54 | 2.47 | 2.22 | 2.05 | 1.91 | 1.8 | 1.79 |
| Surprise | 0.33 | 0.113 | 0.5925 | 0.5646 | 0.23 | 0.21 | 0.73 | 0.24 | 0.17 | 0.02 | 0.47 | 0.33 |
| Surprise Percentage | 9.3484% | 3.7793% | 19.2526% | 18.1153% | 8.2734% | 8.2677% | 29.5547% | 10.8108% | 8.2927% | 1.0471% | 26.1111% | 18.4358% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 4.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2025-12-28 13:09:41
PineStone Asset Management Inc. reduced its stake in Medpace Holdings, Inc. by 19.6% in the third quarter, while institutional investors collectively own 77.98% of the stock. Despite significant insider selling over the past three months, Medpace's fundamentals remain strong, with the company beating Q3 earnings expectations and providing optimistic FY2025 EPS guidance. Wall Street analysts currently give the stock a "Hold" rating with an average target price of $490.82.
2025-12-28 09:09:14
Cwm LLC significantly increased its stake in Medpace Holdings, Inc. ($MEDP) by 311.4% in Q3, now owning 28,496 shares valued at $14.65 million. Despite substantial insider selling that totaled $233.39 million, institutional ownership remains high, and Medpace recently exceeded EPS and revenue estimates, providing optimistic FY2025 guidance. Wall Street analysts currently hold a mixed "Hold" rating with an average target price of $490.82.
2025-12-27 12:09:14
Rice Hall James & Associates LLC reduced its stake in Medpace Holdings, Inc. by 10.8% in Q3, selling 11,045 shares and retaining 91,409 shares valued at $46.999 million. This adjustment makes Medpace its 4th-largest holding, representing about 2.6% of its portfolio. Despite this reduction and recent significant insider selling, Medpace exceeded Q3 earnings and revenue estimates, though analyst consensus remains a "Hold" with a price target below current share price.
2025-12-27 10:09:14
Pacer Advisors Inc. significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 159.4%, purchasing 68,384 additional shares to own a total of 111,290 shares valued at approximately $57.22 million. Despite this institutional buying, Medpace has seen substantial insider selling, with President Jesse J. Geiger and CEO August J. Troendle collectively offloading over 80,000 shares worth millions. The company recently exceeded Q3 earnings estimates and provided optimistic FY2025 guidance, yet analysts maintain a consensus "Hold" rating with a price target of $490.82.
2025-12-23 11:10:17
This article estimates the intrinsic value of Medpace Holdings, Inc. (NASDAQ: MEDP) using a 2-stage Discounted Cash Flow (DCF) model and concluding it trades close to its estimated fair value of US$678. The analysis incorporates future cash flow forecasts and discusses key assumptions like the discount rate and growth phases. It also includes a brief SWOT analysis and advises investors to consider additional factors beyond valuation.
2025-12-23 11:09:39
Brighton Jones LLC significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, acquiring an additional 2,501 shares to bring its total holding to 4,060 shares valued at approximately $2.09 million. This acquisition occurred amidst Medpace's strong Q3 performance, where it surpassed earnings and revenue expectations and provided optimistic FY2025 guidance. Despite recent insider selling activities totaling roughly $233.4 million, institutional ownership of Medpace remains high at 77.98%.
